It is one of the oldest debates in economics: what is the difference between what something costs and what it is worth? In Ireland, that debate has been given new urgency by Kalydeco, a drug used to treat cystic fibrosis.
Kalydeco is a revolutionary drug that will transform the lives of patients who have at least one copy of the G551D mutation - the so-called Celtic gene mutation.
The manufacturer, Vertex Pharmaceuticals, priced Kayldeco...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team